Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

  • Andrzej Lange,
  • Emilia Jaskula,
  • Janusz Lange,
  • Grzegorz Dworacki,
  • Dorota Nowak,
  • Aleksandra Simiczyjew,
  • Monika Mordak-Domagala,
  • Mariola Sedzimirska
  • Article
  • Metrics
  • Comments
  • Media Coverage

The following information is missing from the Funding section: Publication of this study was supported by Wroclaw Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years 2014–2018.

Reference

  1. 1. Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczyjew A, et al. (2018) The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(1): e0190525. https://doi.org/10.1371/journal.pone.0190525 pmid:29304116

Citation: Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczyjew A, et al. (2018) Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(12): e0209108. https://doi.org/10.1371/journal.pone.0209108

Published: December 6, 2018

Copyright: © 2018 Lange et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.